Nevertheless, almost all studies have been focused on the analysis of TME, investigating CD3 and CD8 tumor-infiltrating lymphocytes in order to evaluate more whether there is a therapeutic window for the application of ICI rather than the actual response to ICI [51,52,53,54,55,56,57]. This evidence concerns the gene CD8A and neoplasm.